U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22ClN3O.2ClH
Molecular Weight 428.783
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMODIAQUINE HYDROCHLORIDE ANHYDROUS

SMILES

Cl.Cl.CCN(CC)CC1=CC(NC2=CC=NC3=C2C=CC(Cl)=C3)=CC=C1O

InChI

InChIKey=ROEBJVHPINPMKL-UHFFFAOYSA-N
InChI=1S/C20H22ClN3O.2ClH/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19;;/h5-12,25H,3-4,13H2,1-2H3,(H,22,23);2*1H

HIDE SMILES / InChI

Molecular Formula C20H22ClN3O
Molecular Weight 355.861
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00613 | https://www.drugs.com/international/amodiaquine.html | https://www.ncbi.nlm.nih.gov/pubmed/9825729 | https://www.ncbi.nlm.nih.gov/pubmed/22949374 | https://www.ncbi.nlm.nih.gov/pubmed/18855526

Amodiaquine is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function. The side effects of amodiaquine are generally minor to moderate and are similar to those of chloroquine. Rarely liver problems or low blood cell levels may occur. When taken in excess headaches, trouble seeing, seizures, and cardiac arrest may occur. After oral administration amodiaquine hydrochloride is rapidly absorbed,and undergoes rapid and extensive metabolism to desethylamodiaquine which concentrates in red blood cells. It is likely that desethylamodiaquine, not amodiaquine, is responsible for most of the observed antimalarial activity, and that the toxic effects of amodiaquine after oral administration may in part be due to desethylamodiaquine.

CNS Activity

Curator's Comment: Although in use for more than 40 year, there exists little information regarding the disposition of amodiaquine in man. Chloroquine, a 4-aminoquinoline derivative which resembles amodiaquine structurally, is widely distributed into the body tissues, especially in liver, spleen, kidney, lungs, brain, and spinal cord.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Heme degradation by glutathione
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Coarsucam

Approved Use

Therapeutic Indication. ARTESUNATE AMODIAQUINE WINTHROP is indicated for the treatment of uncomplicated cases of malaria due to Plasmodium falciparum strains which are susceptible to amodiaquine as well as to artesunate.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
21 mg/L
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
322 mg/L
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
415 mg/L
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
77 ng × h/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.7 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10.1 h
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.1 h
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AMODIAQUINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
270 mg 1 times / day steady-state, oral
dose: 270 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ARTESUNATE
AMODIAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
73.4 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 73.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.4 mg, 1 times / day
Sources:
unhealthy, 17 to 76 years
n = 7
Health Status: unhealthy
Condition: malaria
Age Group: 17 to 76 years
Sex: M+F
Population Size: 7
Sources:
Other AEs: Agranulocytosis...
Other AEs:
Agranulocytosis
Sources:
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 15
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 15
Sources:
Disc. AE: Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (6.7%)
Sources:
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 7
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 7
Sources:
Other AEs: Leucopenia, Neutropenia...
Other AEs:
Leucopenia (grade 1, 14%)
Neutropenia (grade 1, 14%)
Sources:
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Co-administed with::
artesunate(4 mg/kg; single dose)
Sources:
healthy, 18 to 45 years
n = 8
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 2, 12%)
Sources:
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 8
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Transaminitis...
Other AEs:
Transaminitis (grade 3, 12%)
Sources:
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (35%)
Vomiting (35%)
Lassitude (grade 2, 60%)
Diarrhoea (15%)
Constipation (10%)
Granulocytopenia (15%)
Sources:
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Other AEs: Weakness generalised, Dizziness...
Other AEs:
Weakness generalised (84%)
Dizziness (58%)
Vomiting (46%)
Itching (32%)
Nausea (26%)
Sources:
71.6 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 71.6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 71.6 mg, 1 times / day
Sources:
unhealthy, median age 35 years
n = 2
Health Status: unhealthy
Condition: malaria
Age Group: median age 35 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Hepatotoxicity...
Other AEs:
Hepatotoxicity
Sources:
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis
73.4 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 73.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.4 mg, 1 times / day
Sources:
unhealthy, 17 to 76 years
n = 7
Health Status: unhealthy
Condition: malaria
Age Group: 17 to 76 years
Sex: M+F
Population Size: 7
Sources:
Hypersensitivity reaction 6.7%
Disc. AE
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 15
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 15
Sources:
Leucopenia grade 1, 14%
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 7
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 7
Sources:
Neutropenia grade 1, 14%
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 7
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 7
Sources:
Neutropenia grade 2, 12%
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Co-administed with::
artesunate(4 mg/kg; single dose)
Sources:
healthy, 18 to 45 years
n = 8
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 8
Sources:
Transaminitis grade 3, 12%
10 mg/kg 1 times / day single, oral
Studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
healthy, 18 to 45 years
n = 8
Health Status: healthy
Age Group: 18 to 45 years
Sex: M+F
Population Size: 8
Sources:
Constipation 10%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Diarrhoea 15%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Granulocytopenia 15%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Nausea 35%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Vomiting 35%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Lassitude grade 2, 60%
45 mg/kg multiple, oral (mean)
Studied dose
Dose: 45 mg/kg
Route: oral
Route: multiple
Dose: 45 mg/kg
Sources:
unhealthy, adult
n = 20
Health Status: unhealthy
Condition: onchocerciasis
Age Group: adult
Sex: M
Population Size: 20
Sources:
Nausea 26%
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Itching 32%
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Vomiting 46%
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Dizziness 58%
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Weakness generalised 84%
600 mg 1 times / day multiple, oral
Studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, median age 20 years
n = 220
Health Status: unhealthy
Condition: malaria
Age Group: median age 20 years
Sex: F
Population Size: 220
Sources:
Hepatotoxicity
71.6 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 71.6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 71.6 mg, 1 times / day
Sources:
unhealthy, median age 35 years
n = 2
Health Status: unhealthy
Condition: malaria
Age Group: median age 35 years
Sex: M+F
Population Size: 2
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: When administered with efavirenz, 125%, 78%, 80%, and 42.15% increase in the Tmax, Cmax AUCT and T1/2 of amodiaquine respectively
minor
minor
minor
minor
minor
minor
minor
minor
no
no
no
no
no
unlikely
unlikely
Comment: Since artesunate is mainly metabolized by CYP2A6, drug–drug interaction between artesunate and AQ is unlikely to occur
yes
PubMed

PubMed

TitleDatePubMed
[Developments in anti-malaria agents: chemical data, structure-activity relationships].
2001 Apr
Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area.
2001 Oct
[National Network study to perpetuate the surveillance of Plasmodium falciparum sensitivity to antimalarials in Madagascar].
2002
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
2002 Apr
[In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)].
2002 Apr
Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial.
2002 Apr 20
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
2002 Dec
Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children.
2002 Feb
The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria.
2002 Jul
Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia.
2002 Nov-Dec
Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium.
2003
Amodiaquine for treating malaria.
2003
Chloroquine efficacy in the treatment of uncomplicated malaria at three sentinel sites in northern Togo.
2003 Dec
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp.
2003 Feb
High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples.
2003 Jan 15
A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
2003 Mar
Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan.
2003 Mar-Apr
Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon.
2003 May 9
[Misunderstood neurological side effects of amodiaquine: apropos of 35 cases in children at Central University Hospital of Yopougon at Abidjan, Côte d' Ivoire].
2003 Nov
The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
2003 Oct
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids.
2003 Sep 1
Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR.
2003 Sep-Dec
Antimalarial drug toxicity: a review.
2004
[Pyrido [3,2-b]indol-4-yl-amines--synthesis and investigation of activity against malaria].
2004 Apr
In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand.
2004 Apr
Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda.
2004 Apr
A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso.
2004 Apr
Can amodiaquine be used safely during pregnancy?
2004 Apr
Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations.
2004 Apr 24
Liquid chromatographic determination of amodiaquine in human plasma.
2004 Apr 25
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.
2004 Feb
Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria.
2004 Feb
Selective and sensitive liquid chromatographic assay of amodiaquine and desethylamodiaquine in whole blood spotted on filter paper.
2004 Jan 5
Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review.
2004 Jan-Mar
Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea.
2004 Mar
Efficacy of pyrimethamine-sulfadoxine in young children with uncomplicated falciparum malaria in rural Burkina Faso.
2004 May 11
A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR.
2004 May 7
Patents

Sample Use Guides

For the treatment of acute malarial attacks in non-immune subjects: 600 mg of the base, followed by 200 mg after 6 hours, then 400 mg daily on each of the subsequent two days. Doses may be taken with meals to lessen gastric upset.
Route of Administration: Oral
In Vitro Use Guide
The FCR3 strain of Plasmodium falciparum was synchronized and cultivated to the trophozoite stage. Synchronized cultures were seeded at the ring stage and allowed to grow for another 20 hr until most parasites reached the trophozoite stage; parasitemia and cell number were determined, and cultures were cultured 6 drug for 1,2,3 and 4 h. One milliliter of culture was washed twice in wash medium (culture medium without plasma, 37°) to remove the drug, and cells were seeded in 24-well culture plates in full culture medium supplemented with 5 mCi/mL of [3H]hypoxanthine. After 4 hr of further cultivation, triplicate samples were transferred into 96-well plates, and parasiteassociated radioactivity was determined using the Filtermate/Matrix 96 Direct Beta counter. Inhibition of parasite growth was calculated compared to untreated controls.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:52:02 UTC 2023
Edited
by admin
on Fri Dec 15 15:52:02 UTC 2023
Record UNII
HOE64181MP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMODIAQUINE HYDROCHLORIDE ANHYDROUS
Common Name English
AMODIAQUINE DIHYDROCHLORIDE, ANHYDROUS
Common Name English
PHENOL, 4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-((DIETHYLAMINO)METHYL)-, DIHYDROCHLORIDE
Common Name English
O-CRESOL, 4-((7-CHLORO-4-QUINOLYL)AMINO)-.ALPHA.-(DIETHYLAMINO)-, DIHYDROCHLORIDE ANHYDROUS
Common Name English
4-((7-CHLORO-4-QUINOLYL)AMINO)-.ALPHA.-(DIETHYLAMINO)-O-CRESOL DIHYDROCHLORIDE
Common Name English
AMODIAQUINE DIHYDROCHLORIDE ANHYDROUS
Common Name English
Code System Code Type Description
PUBCHEM
6246
Created by admin on Fri Dec 15 15:52:03 UTC 2023 , Edited by admin on Fri Dec 15 15:52:03 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-706-0
Created by admin on Fri Dec 15 15:52:03 UTC 2023 , Edited by admin on Fri Dec 15 15:52:03 UTC 2023
PRIMARY
EPA CompTox
DTXSID20219036
Created by admin on Fri Dec 15 15:52:03 UTC 2023 , Edited by admin on Fri Dec 15 15:52:03 UTC 2023
PRIMARY
FDA UNII
HOE64181MP
Created by admin on Fri Dec 15 15:52:03 UTC 2023 , Edited by admin on Fri Dec 15 15:52:03 UTC 2023
PRIMARY
CAS
69-44-3
Created by admin on Fri Dec 15 15:52:03 UTC 2023 , Edited by admin on Fri Dec 15 15:52:03 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY